Summary Mission Therapeutics Ltd (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, neurodegeneration, inflammation and others. the company uses its proprietaryDUB platform to generate small-molecule drug candidates that have clinical and commercial potential.The company receives grants to support the discovery and preclinical development of inhibitors directed against a specific DUB. It operates research facility in Cambridge. Mission is headquartered in Cambridge, the UK.
Mission Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
529 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Down Syndrome (Genetic Disorders) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Drugs in Development, 2021, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape. Down syndrome is a genetic disorder...
240 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Human Reproductive Technologies Market to Reach $28.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Human Reproductive Technologies estimated at US$26.1 Billion in the year 2020, is projected to reach a revised size of US$28.2 Billion by 2027, growing at aCAGR of 1.1% over the...
Left Ventricular Dysfunction (Cardiovascular) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Drugs in Development, 2021, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left...
Hepatic Encephalopathy (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic...
359 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- A Lesson Taught by the Pandemic is the Need to Have Better Health Systems & More Effective Drugs. GPCRs to Reach $3.8 Billion On the Back of Increased Drug R&D Spending
- The global market for G-Protein Coupled Receptors (GPCRs) is projected to reach US$3.8 billion by the year 2027, trailing a post COVID-19...
314 pages •
By Global Industry Analysts
• Jan 2021
Project Details:
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 16
- Influencer Pool: 1653
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
Pharmaceutical
Drug Development
Clinical Trial
World
Health Provider Density
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.